Literature DB >> 28881030

The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction.

Whitney Burns1, Nathanael Koelper1,2, Andrea Barberio3, Mary Deagostino-Kelly1, Michael Mennuti1, Mary D Sammel1,4, Lorraine Dugoff1.   

Abstract

OBJECTIVES: The objective of this study was to identify maternal characteristics associated with a failed cell-free DNA (cfDNA) test due to a low fetal fraction (FF).
METHOD: Retrospective cohort study of women with singleton pregnancies who had cfDNA screening at 10-25 weeks gestation between October 2011 and January 2016. cfDNA screening was performed using methylation techniques until October 2013; thereafter, samples were run with massively parallel sequencing. Multivariable logistic regression was performed to identify maternal characteristics associated with no cell free DNA result secondary to low FF.
RESULTS: Thirty-three (1.2%) of 2890 eligible women had a failed cfDNA test, including 18 (0.6%) cases with a low FF. A failed cfDNA test due to a low FF was associated with obesity (aOR 1.11, CI 1.05-1.18, p = 0.0003) and treatment with enoxaparin (aOR 37.5, 11.19-125.87, p < 0.0001). 5 of 28 (18%, 95% CI: 6.1%-36.9%) women on enoxaparin had a failed cfDNA test secondary to a low FFx.
CONCLUSION: Enoxaparin therapy and obesity were associated with an increased incidence of a failed cfDNA test due to low FF. Further research is needed to determine the mechanism by which anticoagulation therapy alters cfDNA test functionality and identify approaches to improve test performance in these women.
© 2017 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28881030     DOI: 10.1002/pd.5152

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  11 in total

1.  Experimental factors are associated with fetal fraction in size selection noninvasive prenatal testing.

Authors:  Longwei Qiao; Jun Mao; Minjuan Liu; Yinghua Liu; Xiaoyan Song; Hui Tang; Qing Zhang; Hong Li; Yaojuan Lu; Yuting Liang; Ting Wang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

2.  The impact of maternal autoimmune disease on cell-free DNA test characteristics.

Authors:  Hayley J MacKinnon; Teodora R Kolarova; Ronit Katz; Jaclynne M Hedge; Elena Vinopal; Christina M Lockwood; Raj Shree; Shani Delaney
Journal:  Am J Obstet Gynecol MFM       Date:  2021-08-18

3.  Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity.

Authors:  Raj Shree; Teodora R Kolarova; Hayley J MacKinnon; Christina M Lockwood; Suchitra Chandrasekaran
Journal:  Am J Obstet Gynecol MFM       Date:  2022-05-27

Review 4.  Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping.

Authors:  Sandra Wienzek-Lischka; Sandy Bachmann; Vanessa Froehner; Gregor Bein
Journal:  Transfus Med Hemother       Date:  2020-01-20       Impact factor: 3.747

5.  Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure.

Authors:  Yohann Dabi; Sarah Guterman; Jacques C Jani; Alexandra Letourneau; Adèle Demain; Pascale Kleinfinger; Laurence Lohmann; Jean-Marc Costa; Alexandra Benachi
Journal:  J Transl Med       Date:  2018-12-03       Impact factor: 5.531

6.  Targeted fetal cell-free DNA screening for aneuploidies in 4,594 pregnancies: Single center study.

Authors:  Altug Koc; Ozge Ozer Kaya; Berk Ozyilmaz; Yasar B Kutbay; Ozgur Kirbiyik; Taha R Ozdemir; Kadri M Erdogan; Merve Saka Guvenc; Deniz C Oztekin; Mehmet Ozeren; Halil G Pala; Atalay Ekin; Cenk Gezer; Alkim G Sahingoz Yildirim; Bahar Konuralp Atakul; Secil Kurtulmus; Ugur Turhan; Cuneyt E Taner
Journal:  Mol Genet Genomic Med       Date:  2019-05-08       Impact factor: 2.183

7.  Combining the use of a fetal fraction-based risk algorithm and probability of an informative redraw in noninvasive prenatal testing for fetal aneuploidy.

Authors:  Peter Benn; Kimberly Martin; Trudy McKanna; Elizabeth Valenti; Paul Billings; Zachary Demko
Journal:  J Genet Couns       Date:  2019-12-23       Impact factor: 2.537

8.  Low fetal fraction in obese women at first trimester cell-free DNA based prenatal screening is not accompanied by differences in total cell-free DNA.

Authors:  Raj Shree; Teodora R Kolarova; Hayley J MacKinnon; Jaclynne M Hedge; Elena Vinopal; Kimberly K Ma; Christina M Lockwood; Suchitra Chandrasekaran
Journal:  Prenat Diagn       Date:  2021-08-14       Impact factor: 3.242

9.  Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening.

Authors:  Herman Hedriana; Kimberly Martin; Daniel Saltzman; Paul Billings; Zachary Demko; Peter Benn
Journal:  Prenat Diagn       Date:  2019-11-21       Impact factor: 3.050

10.  Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood.

Authors:  Joost C de Vries; Arjan D Barendrecht; Chantal C Clark; Rolf T Urbanus; Peter Boross; Steven de Maat; Coen Maas
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.